0001209191-21-024791.txt : 20210402
0001209191-21-024791.hdr.sgml : 20210402
20210402183349
ACCESSION NUMBER: 0001209191-21-024791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210331
FILED AS OF DATE: 20210402
DATE AS OF CHANGE: 20210402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WINSTON ROY
CENTRAL INDEX KEY: 0001751757
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 21803307
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-31
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001751757
WINSTON ROY
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
Chief Clinical Officer
Common Stock
2021-03-31
4
M
0
13750
34.375
A
48535
D
Common Stock
2021-03-31
4
S
0
16363
70.36
D
32172
D
Common Stock
2021-03-31
4
S
0
4661
71.09
D
27511
D
Common Stock
2021-03-31
4
S
0
1200
72.12
D
26311
D
Stock Option (Right to Buy)
34.375
2021-03-31
4
M
0
13750
0.00
D
2028-05-02
Common Stock
13750
6250
D
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.80 to $70.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 through 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.80 to $71.79, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.80 to $72.48, inclusive.
The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
/s/ Kristen Williams, Attorney-in-Fact
2021-04-02